A Carnot Institute devoted to lymphoma: creating synergies,
initiating partnerships, accelerating translational research
Target markets
•
Pharma
•
Biotech
•
In vitro diagnosis
•
Imaging
Expertises
and competences
The integrated expertise and
competences within CALYM
enable to cover all stages of
lymphoma research and
development of therapeutics
and biomarkers, from basic
to clinical research.
www.calym.org
The Consortium for the acceleration of innovation
and its transfer in the lymphoma field
The CALYM Carnot Institute brings together 13 research
teams specialized in lymphoma, most frequent blood cancer.
Its objective is to accelerate innovation and its transfer
in the lymphoma field through a reinforced public-private
partnership and a unique R&D offer from identification of new
cellular targets to international phase III registration trials.
From the identification of
new biological targets
to registration trials
Consortium overview
2 non-profit research organizations
A world-renowned cooperative
group, LYSA (The Lymphoma Study
Association)
Europe’s leading academic clinical
research organization : LYSARC
(The Lymphoma Academic Research
Organisation)
LYSA and LYSARC are together
accredited «French cooperative
intergroup of international dimension
in the field of cancer» by the French
National Cancer Institute
11 public research labs
(belonging to INSERM or CNRS national
research bodies, to universities, and/
or to hospitals) having an A+ or A grade
from the French Agency for Research
and Higher Education Evaluation